

## SUPPLEMENTARY FIGURES




**Supplementary Figure 1. Panther pathway-based GSEA of** *ARHGAP30* **in lung adenocarcinoma (LUAD).** (A) Bar chart of Panther Pathway-based GSEA of *ARHGAP30* in LUAD (FDR < 0.05). (B1–B14) GSEA enrichment analysis Plots of 14 tumor immune-related Panther Pathway gene sets (FDR < 0.05).




Supplementary Figure 2. Reactome pathway-based GSEA of *ARHGAP30* in lung adenocarcinoma (LUAD). (A) Bar chart of Reactome Pathway-based GSEA of *ARHGAP30* in LUAD (FDR < 0.05). (B1–B18) GSEA enrichment analysis Plots of 18 tumor immune-related Reactome Pathway gene sets (FDR < 0.05).


2




**Supplementary Figure 3. Wikipathway-based GSEA of** *ARHGAP30* **in lung adenocarcinoma (LUAD).** (A) Bar chart of Wikipathwaybased GSEA of *ARHGAP30* in LUAD (FDR < 0.05). (B1–B18) GSEA enrichment analysis Plots of 18 tumor immune-related Wikipathway gene sets (FDR < 0.05).




Supplementary Figure 4. Gene ontology biological process-based GSEA of *ARHGAP30* in lung adenocarcinoma (LUAD). (A) Bar chart of Gene Ontology Biological Process-based GSEA of *ARHGAP30* in LUAD (FDR < 0.05). (B1–B18) GSEA enrichment analysis plots of 18 tumors immune-related Gene Ontology Biological Process gene sets (FDR < 0.05).




Supplementary Figure 5. Gene ontology cellular component-based GSEA of *ARHGAP30* in lung adenocarcinoma (LUAD). (A) Bar chart of Gene Ontology Cellular Component-based GSEA of *ARHGAP30* in LUAD (FDR < 0.05). (B1–B18) GSEA enrichment analysis plots of 18 tumors immune-related Gene Ontology Cellular Component gene sets (FDR < 0.05).




**Supplementary Figure 6. Gene ontology molecular function-based GSEA of** *ARHGAP30* **in lung adenocarcinoma (LUAD).** (A) Bar chart of Gene Ontology Molecular Function-based GSEA of *ARHGAP30* **in LUAD** (FDR < 0.05). (**B1–B18**) GSEA enrichment analysis plots of 18 tumors immune-related Gene Ontology Molecular Function gene sets (FDR < 0.05).



**Supplementary Figure 7. Kinase target network-based GSEA of** *ARHGAP30* **in lung adenocarcinoma (LUAD).** (A) Bar chart of Kinase Target Network-based GSEA of *ARHGAP30* in LUAD (FDR < 0.05). (**B1–B10**) GSEA enrichment analysis plots of 10 tumor immune-related Kinase Target Network gene sets (FDR < 0.05).




Supplementary Figure 8. Transcription factor network-based GSEA of *ARHGAP30* in lung adenocarcinoma (LUAD). (A) Bar chart of Transcription Factor Network-based GSEA of *ARHGAP30* in LUAD (FDR < 0.05). (B1–B17) GSEA enrichment analysis plots of 17 tumor immune-related Transcription Factor Network gene sets (FDR < 0.05).




**Supplementary Figure 9. PPI BIOGRID network-based GSEA of** *ARHGAP30* in lung adenocarcinoma (LUAD). (A) Bar chart of PPI BIOGRID Network-based GSEA of *ARHGAP30* in LUAD (FDR < 0.05). (B1–B18) GSEA enrichment analysis plots of 18 tumor immune-related PPI BIOGRID Network gene sets (FDR < 0.05).


9




**Supplementary Figure 10. The correlation between the expression of** *ARHGAP30* and MHC molecules. (A) Heat map of Spearman correlations between *ARHGAP30* expression and MHC molecules across human cancers. (B1–B39) Scatter plots showing the positive correlation between *ARHGAP30* expression and MHC molecules in the treatment of lung adenocarcinoma.



**Supplementary Figure 11. The correlation between the DNA methylation of** *ARHGAP30* **and MHC molecules.** (A) Heat map of Spearman correlations between DNA methylation of *ARHGAP30* and MHC molecules across human cancers. (B1–B21) Scatter plots showing the negative correlation between DNA methylation of *ARHGAP30* and MHC molecules in the treatment of lung adenocarcinoma.



**Supplementary Figure 12. The correlation between the expression of** *ARHGAP30* **and chemokines.** (A) Heat map of Spearman correlations between *ARHGAP30* expression and chemokines across human cancers. (B1–B30) Scatter plots showing the positive correlation between *ARHGAP30* expression and chemokines in the treatment of lung adenocarcinoma.



**Supplementary Figure 13. The correlation between the expression of** *ARHGAP30* **and Chemokine Receptors.** (A) Heat map of Spearman correlations between *ARHGAP30* expression and chemokine receptors across human cancers. (B1–B15) Scatter plots showing the positive correlation between *ARHGAP30* expression and chemokine receptors in the treatment of lung adenocarcinoma.